Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
Clearmind Medicine (Nasdaq: CMND) filed an Israeli patent application on Nov 17, 2025 for a novel combination therapy pairing MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines such as Palmitoylethanolamide (PEA) to address depression.
The filing arises from Clearmind's collaboration with Neurothera Labs and expands a portfolio that already includes 13 patents tied to MEAI–N-Acylethanolamine combinations for conditions including alcohol use disorder, cocaine addiction, obesity and depression. Clearmind said preclinical data support MEAI's efficacy in reducing addictive behaviors while preserving normal reward pathways.
Clearmind Medicine (Nasdaq: CMND) ha depositato una domanda di brevetto israeliana il 17 novembre 2025 per una nuova terapia combinata che abbina MEAI (5-metossi-2-amminoindano) a N-Acylethanolamines, come la Palmitoiletanolamida (PEA), per affrontare la depressione.
La domanda nasce dalla collaborazione di Clearmind con Neurothera Labs e amplia un portafoglio che comprende già 13 brevetti legati a combinazioni MEAI–N-Acylethanolamine per condizioni quali disturbo da uso di alcol, dipendenza da cocaina, obesità e depressione. Clearmind ha dichiarato che i dati preclinici supportano l'efficacia di MEAI nel ridurre i comportamenti dipendenti preservando al contempo i normali circuiti di ricompensa.
Clearmind Medicine (Nasdaq: CMND) presentó una solicitud de patente israelí el 17 de noviembre de 2025 para una nueva terapia de combinación que asocia MEAI (5-metoxi-2-aminoindano) con N-Acylethanolamines, como la Palmitoiletanolamida (PEA), para abordar la depresión.
La presentación se deriva de la colaboración de Clearmind con Neurothera Labs y amplía un portafolio que ya incluye 13 patentes relacionadas con combinaciones MEAI–N-Acylethanolamine para condiciones que incluyen trastorno por uso de alcohol, adicción a la cocaína, obesidad y depresión. Clearmind dijo que datos preclínicos respaldan la eficacia de MEAI para reducir comportamientos adictivos mientras se conservan las vías de recompensa normales.
Clearmind Medicine (Nasdaq: CMND) 는 2025년 11월 17일에 이스라엘 특허 출원을 제시했습니다. 이 새로운 조합 치료법은 MEAI (5-메톡시-2-아미노인다인)와 N-아실에탄올아민 계열의 물질들, 예를 들어 팔미톨에탄올아미드(PEA)를 결합하여 우울증을 다루는 것을 목표로 합니다.
이 출원은 Clearmind와 Neurothera Labs의 협력에서 비롯되었으며, MEAI–N-Acylethanolamine 결합과 관련된 13개의 특허를 포함하는 포트폴리오를 확장합니다. 이 특허들은 알코올 사용 장애, 코카인 중독, 비만 및 우울증과 같은 조건들을 다룹니다. Clearmind는 전임상 데이터가 MEAI가 중독 행동을 줄이면서 정상적인 보상 경로를 보존하는 데 효과적임을 뒷받침한다고 밝혔습니다.
Clearmind Medicine (Nasdaq: CMND) a déposé une demande de brevet israélienne le 17 novembre 2025 pour une thérapie combinée innovante associant MEAI (5-méthoxy-2-aminoindane) à des N-Acylethanolamines telles que la Palmitoyléthanolamide (PEA) afin de traiter la dépression.
Le dépôt résulte de la collaboration de Clearmind avec Neurothera Labs et étend un portefeuille qui compte déjà 13 brevets liés à des combinaisons MEAI–N-Acylethanolamine pour des conditions telles que les troubles liés à l’alcool, la dépendance à la cocaïne, l’obésité et la dépression. Clearmind a déclaré que les données précliniques soutiennent l’efficacité du MEAI à réduire les comportements addictifs tout en préservant les voies de récompense normales.
Clearmind Medicine (Nasdaq: CMND) hat am 17. November 2025 einen israelischen Patentantrag für eine neuartige Kombinationstherapie eingereicht, die MEAI (5-Methoxy-2-Aminindan) mit N-Acylethanolaminen wie Palmitoylethanolamid (PEA) zur Behandlung von Depressionen verbindet.
Die Einreichung resultiert aus Clearminds Zusammenarbeit mit Neurothera Labs und erweitert ein Portfolio, das bereits 13 Patente im Zusammenhang mit MEAI–N-Acylethanolaminen-Kombinationen für Erkrankungen wie Alkoholkonsumstörung, Kokainabhängigkeit, Fettleibigkeit und Depression umfasst. Clearmind sagte, präklinische Daten unterstützten die Wirksamkeit von MEAI bei der Reduktion süchtig machenden Verhaltens, während normale Belohnungspfade erhalten blieben.
Clearmind Medicine (Nasdaq: CMND) قدمت طلب براءة اختراع إسرائيلية في 17 نوفمبر 2025 لعلاج تركيبي جديد يجمع MEAI (5-ميثوكسي-2-أمينوإندي) مع N-أكايليثانولأمينات مثل Palmitoylethanolamide (PEA) لمعالجة الاكتئاب.
originates from collaboration with Neurothera Labs وتُوسع محفظة لديها حالياً 13 براءة اختراع متعلقة بتوليفات MEAI–N-Acylethanolamine لحالات تشمل اضطراب استخدام الكحول، الإدمان على الكوكايين، السمنة والاكتئاب. وقالت Clearmind إن البيانات قبل السريرية تدعم فاعلية MEAI في تقليل السلوكيات الإدمانية مع الحفاظ على مسارات المكافأة الطبيعية.
- None.
- None.
Insights
Clearmind filed an Israeli patent for a MEAI+PEA non‑hallucinogenic depression therapy, strengthening early IP amid preclinical-stage work.
The filing formalizes an intellectual property claim around a combination of MEAI and Palmitoylethanolamide (PEA) for depression and expands a portfolio tied to the collaboration with Neurothera Labs Inc.. The business mechanism is simple: broader patent coverage can increase an asset’s exclusionary value ahead of clinical development by limiting competitors and improving negotiation leverage for partnerships or licensing.
Dependencies and risks include the obvious limits of a patent filing: it does not guarantee patent grant, clinical efficacy, or regulatory progress. The disclosure notes only preclinical support and no clinical data; therefore the commercial value depends on later translational milestones. Watch for progression to clinical studies, regulatory filings, and any issued patents; expect meaningful signals on timing and value in the next 12–36 months.
Vancouver, Canada, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.
The patent application stems from Clearmind’s collaboration with Neurothera Labs Inc. (TSXV: NTLX) (“Neurothera”), a subsidiary of SciSparc Ltd. (Nasdaq: SPRC). This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.
“This patent application marks another important milestone in our mission to develop novel, science-backed solutions for some of the world’s most challenging mental health conditions,” said Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine. “Depression affects hundreds of millions of people globally, yet treatment innovation has lagged for decades. We believe that our work with Neurothera continues to generate promising therapeutic pathways, and this new filing further strengthens our IP position as we advance MEAI-based treatments toward clinical development.”
This new filing expands Clearmind’s growing intellectual property portfolio. The Company has filed 13 patents related to its collaboration with Neurothera, focusing, among others, on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its growing intellectual property portfolio, its mission to develop novel, science-backed solutions for some of the world’s most challenging mental health conditions and advancing MEAI-based treatments toward clinical development. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind (CMND) announce on November 17, 2025 about MEAI and PEA?
How many patents has Clearmind filed related to its collaboration with Neurothera?
Does the Clearmind patent filing affect clinical development timelines for CMND therapies?
What evidence did Clearmind cite to support MEAI's potential benefits in CMND's announcement?
Who collaborated with Clearmind on the Israeli patent application for MEAI–PEA?
What conditions besides depression are covered by Clearmind's MEAI-related patents?
